# EGAIN Corp: financial statements, quarterly

EGAN · Nasdaq · CIK 1066194 · [Technology](/sectors/technology.md) · fiscal year ends Jun 30

Pages: [Overview](/companies/egan.md) · [Financials](/companies/egan/financials.md) · [Filings](/companies/egan/filings.md) · [Insiders](/companies/egan/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/egan/financials.md?period=annual).

## Income statement

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [24.2](/filings/0001558370-24-015305.md) | [23.8](/filings/0001558370-25-000941.md) | [22.4](/filings/0001558370-25-007758.md) | [22.5](/filings/0001558370-24-012767.md) | [21.8](/filings/0001104659-25-110385.md) | [22.4](/filings/0001104659-26-009755.md) | [21.0](/filings/0001104659-26-061184.md) | [23.2 d](/filings/0001104659-26-106739.md) | [23.5](/filings/0001104659-25-110385.md) | [23.0](/filings/0001104659-26-009755.md) | [22.5](/filings/0001104659-26-061184.md) | [22.2 d](/filings/0001104659-26-106739.md) |
| Cost of revenue | $m | [6.8](/filings/0001558370-24-015305.md) | [7.0](/filings/0001558370-25-000941.md) | [6.9](/filings/0001558370-25-007758.md) | [6.9 d](/filings/0001104659-25-089540.md) | [6.7](/filings/0001104659-25-110385.md) | [6.7](/filings/0001104659-26-009755.md) | [6.7](/filings/0001104659-26-061184.md) | [6.4 d](/filings/0001104659-26-106739.md) | [5.8](/filings/0001104659-25-110385.md) | [6.2](/filings/0001104659-26-009755.md) | [6.0](/filings/0001104659-26-061184.md) | [6.3 d](/filings/0001104659-26-106739.md) |
| Gross profit | $m | [17.3](/filings/0001558370-24-015305.md) | [16.8](/filings/0001558370-25-000941.md) | [15.5](/filings/0001558370-25-007758.md) | [15.6](/filings/0001558370-24-012767.md) | [15.1](/filings/0001104659-25-110385.md) | [15.7](/filings/0001104659-26-009755.md) | [14.3](/filings/0001104659-26-061184.md) | [16.9 d](/filings/0001104659-26-106739.md) | [17.7](/filings/0001104659-25-110385.md) | [16.8](/filings/0001104659-26-009755.md) | [16.5](/filings/0001104659-26-061184.md) | [15.9 d](/filings/0001104659-26-106739.md) |
| Research and development | $m | [6.6](/filings/0001558370-24-015305.md) | [6.7](/filings/0001558370-25-000941.md) | [6.7](/filings/0001558370-25-007758.md) | [6.7 d](/filings/0001104659-25-089540.md) | [7.4](/filings/0001104659-25-110385.md) | [7.7](/filings/0001104659-26-009755.md) | [7.5](/filings/0001104659-26-061184.md) | [7.0 d](/filings/0001104659-26-106739.md) | [7.3](/filings/0001104659-25-110385.md) | [7.3](/filings/0001104659-26-009755.md) | [7.6](/filings/0001104659-26-061184.md) | [7.3 d](/filings/0001104659-26-106739.md) |
| Operating income | $m | [1.4](/filings/0001558370-24-015305.md) | [2.4](/filings/0001558370-25-000941.md) | [0.9](/filings/0001558370-25-007758.md) | [1.2](/filings/0001558370-24-012767.md) | [0.5](/filings/0001104659-25-110385.md) | [0.7](/filings/0001104659-26-009755.md) | [0.0](/filings/0001104659-26-061184.md) | [3.2 d](/filings/0001104659-26-106739.md) | [2.8](/filings/0001104659-25-110385.md) | [2.0](/filings/0001104659-26-009755.md) | [2.0](/filings/0001104659-26-061184.md) | [1.1 d](/filings/0001104659-26-106739.md) |
| Income tax | $m | [0.4](/filings/0001558370-24-015305.md) | [0.5](/filings/0001558370-25-000941.md) | [0.5](/filings/0001558370-25-007758.md) | [0.5 d](/filings/0001104659-25-089540.md) | [0.5](/filings/0001104659-25-110385.md) | [0.2](/filings/0001104659-26-009755.md) | [0.3](/filings/0001104659-26-061184.md) | [(27.6) d](/filings/0001104659-26-106739.md) | [0.9](/filings/0001104659-25-110385.md) | [0.3](/filings/0001104659-26-009755.md) | [0.4](/filings/0001104659-26-061184.md) | [0.3 d](/filings/0001104659-26-106739.md) |
| Net income | $m | [2.6](/filings/0001558370-24-015305.md) | [2.2](/filings/0001558370-25-000941.md) | [1.5](/filings/0001558370-25-007758.md) | [1.5](/filings/0001558370-24-012767.md) | [0.7](/filings/0001104659-25-110385.md) | [0.7](/filings/0001104659-26-009755.md) | [0.1](/filings/0001104659-26-061184.md) | [30.9 d](/filings/0001104659-26-106739.md) | [2.8](/filings/0001104659-25-110385.md) | [2.3](/filings/0001104659-26-009755.md) | [2.4](/filings/0001104659-26-061184.md) | [1.3 d](/filings/0001104659-26-106739.md) |
| Diluted EPS | $ per share | [0.08](/filings/0001558370-24-015305.md) | [0.07](/filings/0001558370-25-000941.md) | [0.05](/filings/0001558370-25-007758.md) | [0.05](/filings/0001558370-24-012767.md) | [0.02](/filings/0001104659-25-110385.md) | [0.02](/filings/0001104659-26-009755.md) | [0.00](/filings/0001104659-26-061184.md) | not reported | [0.10](/filings/0001104659-25-110385.md) | [0.08](/filings/0001104659-26-009755.md) | [0.09](/filings/0001104659-26-061184.md) | not reported |
| Basic EPS | $ per share | [0.08](/filings/0001558370-24-015305.md) | [0.07](/filings/0001558370-25-000941.md) | [0.05](/filings/0001558370-25-007758.md) | [0.05](/filings/0001558370-24-012767.md) | [0.02](/filings/0001104659-25-110385.md) | [0.02](/filings/0001104659-26-009755.md) | [0.00](/filings/0001104659-26-061184.md) | not reported | [0.10](/filings/0001104659-25-110385.md) | [0.09](/filings/0001104659-26-009755.md) | [0.09](/filings/0001104659-26-061184.md) | not reported |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [79.8](/filings/0001558370-23-017979.md) | [86.8](/filings/0001558370-24-000894.md) | [83.0](/filings/0001558370-24-007595.md) | [70.0](/filings/0001104659-25-089540.md) | [67.2](/filings/0001558370-24-015305.md) | [70.5](/filings/0001558370-25-000941.md) | [68.7](/filings/0001558370-25-007758.md) | [62.9](/filings/0001104659-26-106739.md) | [70.9](/filings/0001104659-25-110385.md) | [83.1](/filings/0001104659-26-009755.md) | [80.5](/filings/0001104659-26-061184.md) | [73.3](/filings/0001104659-26-106739.md) |
| Current assets | $m | [103](/filings/0001558370-23-017979.md) | [106](/filings/0001558370-24-000894.md) | [98.9](/filings/0001558370-24-007595.md) | [107](/filings/0001104659-25-089540.md) | [94.7](/filings/0001558370-24-015305.md) | [90.7](/filings/0001558370-25-000941.md) | [85.8](/filings/0001558370-25-007758.md) | [101](/filings/0001104659-26-106739.md) | [98.2](/filings/0001104659-25-110385.md) | [100](/filings/0001104659-26-009755.md) | [93.1](/filings/0001104659-26-061184.md) | [102](/filings/0001104659-26-106739.md) |
| Total assets | $m | [123](/filings/0001558370-23-017979.md) | [125](/filings/0001558370-24-000894.md) | [120](/filings/0001558370-24-007595.md) | [128](/filings/0001104659-25-089540.md) | [115](/filings/0001558370-24-015305.md) | [111](/filings/0001558370-25-000941.md) | [106](/filings/0001558370-25-007758.md) | [148](/filings/0001104659-26-106739.md) | [145](/filings/0001104659-25-110385.md) | [147](/filings/0001104659-26-009755.md) | [140](/filings/0001104659-26-061184.md) | [148](/filings/0001104659-26-106739.md) |
| Current liabilities | $m | [53.8](/filings/0001558370-23-017979.md) | [53.3](/filings/0001558370-24-000894.md) | [49.6](/filings/0001558370-24-007595.md) | [62.6](/filings/0001104659-25-089540.md) | [52.9](/filings/0001558370-24-015305.md) | [49.3](/filings/0001558370-25-000941.md) | [49.7](/filings/0001558370-25-007758.md) | [62.2](/filings/0001104659-26-106739.md) | [55.9](/filings/0001104659-25-110385.md) | [52.8](/filings/0001104659-26-009755.md) | [43.3](/filings/0001104659-26-061184.md) | [59.1](/filings/0001104659-26-106739.md) |
| Total liabilities | $m | [58.7](/filings/0001558370-23-017979.md) | [58.7](/filings/0001558370-24-000894.md) | [56.5](/filings/0001558370-24-007595.md) | [69.4](/filings/0001104659-25-089540.md) | [59.2](/filings/0001558370-24-015305.md) | [56.0](/filings/0001558370-25-000941.md) | [54.6](/filings/0001558370-25-007758.md) | [67.3](/filings/0001104659-26-106739.md) | [61.1](/filings/0001104659-25-110385.md) | [58.0](/filings/0001104659-26-009755.md) | [48.1](/filings/0001104659-26-061184.md) | [63.8](/filings/0001104659-26-106739.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [64.3](/filings/0001558370-25-000941.md) | [66.8](/filings/0001558370-25-007758.md) | [63.9](/filings/0001558370-25-007758.md) | [58.5](/filings/0001104659-26-106739.md) | [55.7](/filings/0001104659-26-009755.md) | [55.3](/filings/0001104659-26-061184.md) | [51.6](/filings/0001104659-26-061184.md) | [80.7](/filings/0001104659-26-106739.md) | [83.5](/filings/0001104659-26-009755.md) | [88.8](/filings/0001104659-26-061184.md) | [91.6](/filings/0001104659-26-061184.md) | [84.2](/filings/0001104659-26-106739.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [8.1](/filings/0001558370-24-015305.md) | [7.7 d](/filings/0001558370-25-000941.md) | [1.7 d](/filings/0001558370-25-007758.md) | [(5.1) d](/filings/0001104659-25-089540.md) | [1.0](/filings/0001104659-25-110385.md) | [6.4 d](/filings/0001104659-26-009755.md) | [2.2 d](/filings/0001104659-26-061184.md) | [(4.3) d](/filings/0001104659-26-106739.md) | [10.4](/filings/0001104659-25-110385.md) | [10.1 d](/filings/0001104659-26-009755.md) | [(1.8) d](/filings/0001104659-26-061184.md) | [2.4 d](/filings/0001104659-26-106739.md) |
| Capital expenditure | $m | [0.0](/filings/0001558370-24-015305.md) | [0.1 d](/filings/0001558370-25-000941.md) | [0.0 d](/filings/0001558370-25-007758.md) | [0.0 d](/filings/0001104659-25-089540.md) | [0.1](/filings/0001104659-25-110385.md) | [0.1 d](/filings/0001104659-26-009755.md) | [0.1 d](/filings/0001104659-26-061184.md) | [0.2 d](/filings/0001104659-26-106739.md) | [0.2](/filings/0001104659-25-110385.md) | [0.2 d](/filings/0001104659-26-009755.md) | [0.1 d](/filings/0001104659-26-061184.md) | [0.1 d](/filings/0001104659-26-106739.md) |
| Share repurchases | $m | [0.5](/filings/0001558370-24-015305.md) | [2.5 d](/filings/0001558370-25-000941.md) | [5.5 d](/filings/0001558370-25-007758.md) | [8.7 d](/filings/0001104659-25-089540.md) | [4.6](/filings/0001104659-25-110385.md) | [2.4 d](/filings/0001104659-26-009755.md) | [5.0 d](/filings/0001104659-26-061184.md) | [3.8 d](/filings/0001104659-26-106739.md) | [1.5](/filings/0001104659-25-110385.md) | [(0.0) d](/filings/0001104659-26-009755.md) | [0.0 d](/filings/0001104659-26-061184.md) | [10.1 d](/filings/0001104659-26-106739.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2022-09-30) | Q2 FY2023 (2022-12-31) | Q3 FY2023 (2023-03-31) | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [31.9](/filings/0001558370-23-017979.md) | [32.0](/filings/0001558370-24-000894.md) | [32.1](/filings/0001558370-24-007595.md) | [32.1](/filings/0001558370-24-015305.md) | [31.8](/filings/0001558370-25-000941.md) | [31.6](/filings/0001558370-25-007758.md) | [29.3](/filings/0001104659-25-110385.md) | [29.1](/filings/0001104659-26-009755.md) | [28.5](/filings/0001104659-26-061184.md) | [27.5](/filings/0001104659-25-110385.md) | [28.3](/filings/0001104659-26-009755.md) | [28.1](/filings/0001104659-26-061184.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 26,171,467 at 2026-09-03, from the cover of the [10-K filed 2026-09-10](/filings/0001104659-26-106739.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:32 ET. No prices; not investment advice.